Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 25, 2026, 7:53 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 745–768 of 1,573 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Biological Control Clear all
Completed No phase listed Observational Accepts healthy volunteers

Real World and Genomic Data Based Asthma Insight Through Network Analysis

NCT06623435
View directory record Official record
Conditions
Asthma
Interventions
Not listed
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
18 Years and older
Enrollment
1,075 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2025
U.S. locations
5
States / cities
Denver, Colorado • New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 18, 2026 · Synced Oct 25, 2026, 7:53 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Impact of Botox Treatment Into the Upper One Third of the Face an Area on Mood and Self -Appearance Satisfaction

NCT04439825
View directory record Official record
Conditions
Mood
Interventions
Botulinum Neurotoxin, Placebo
Drug
Lead sponsor
DeNova Research
Other
Eligibility
10 Years to 75 Years
Enrollment
45 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Mar 15, 2021 · Synced Oct 25, 2026, 7:53 AM EDT
Recruiting Phase 4 Interventional

Low-Dose Short-Term Ketorolac to Reduce Chronic Opioid Use in Orthopaedic Polytrauma Patients

NCT06201676
View directory record Official record
Conditions
Orthopaedic Trauma, Chronic Opioid Use
Interventions
Ketorolac Injection, Standard of Care (SOC) Multimodal Analgesia
Drug · Other
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 70 Years
Enrollment
458 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
2
States / cities
Boston, Massachusetts • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated May 14, 2026 · Synced Oct 25, 2026, 7:53 AM EDT
Active, not recruiting Phase 2Phase 3 Interventional

AMNIOX CORD Study - Radical Prostatectomy With and Without Cryopreserved Umbilical Cord Allograft

NCT04263025
View directory record Official record
Conditions
Prostate Cancer
Interventions
Cryopreserved Umbilical Cord Allograft, Robot-Assisted Radical Prostatectomy
Biological · Procedure
Lead sponsor
Hackensack Meridian Health
Other
Eligibility
30 Years to 70 Years · Male only
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
1
States / cities
Hackensack, New Jersey
Source: ClinicalTrials.gov public record
Updated May 26, 2026 · Synced Oct 25, 2026, 7:53 AM EDT
Completed Phase 3 Interventional

Evaluation of Fibrin Sealant 2 in Retroperitoneal or Intra-Abdominal Surgery

NCT00307515
View directory record Official record
Conditions
Blood Loss, Surgical
Interventions
Fibrin Sealant 2 (FS2), Oxidized Regenerated Cellulose (Surgicel)
Drug · Device
Lead sponsor
Ethicon, Inc.
Industry
Eligibility
Not listed
Enrollment
135 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006
U.S. locations
16
States / cities
Los Angeles, California • Jacksonville, Florida • Miami, Florida + 12 more
Source: ClinicalTrials.gov public record
Updated Jan 9, 2009 · Synced Oct 25, 2026, 7:53 AM EDT
Completed Phase 3 Interventional Results available

A Phase 3 Study of LJPC-501 in Patients With Catecholamine-Resistant Hypotension

NCT02338843
View directory record Official record
Conditions
Catecholamine-resistant Hypotension (CRH), Distributive Shock, High Output Shock, Sepsis
Interventions
LJPC-501, Placebo
Drug
Lead sponsor
La Jolla Pharmaceutical Company
Industry
Eligibility
18 Years and older
Enrollment
344 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
52
States / cities
Mobile, Alabama • Phoenix, Arizona • Loma Linda, California + 39 more
Source: ClinicalTrials.gov public record
Updated Mar 27, 2018 · Synced Oct 25, 2026, 7:53 AM EDT
Terminated Phase 2 Interventional Results available

Assess Functional Outcomes in Anemic, Critically Ill, Trauma Patients When Taking Epoetin Alfa

NCT00210626
View directory record Official record
Conditions
Anemia
Interventions
PROCRIT, Placebo
Drug
Lead sponsor
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Industry
Eligibility
18 Years to 55 Years
Enrollment
192 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
21
States / cities
Birmingham, Alabama • Orange, California • Santa Barbara, California + 18 more
Source: ClinicalTrials.gov public record
Updated Apr 21, 2014 · Synced Oct 25, 2026, 7:53 AM EDT
Completed Phase 3 Interventional Results available

A Study of an Ad26.RSV.preF-based Vaccine and High-dose Seasonal Influenza Vaccine, With and Without Coadministration, in Adults Aged 65 Years and Older

NCT05071313
View directory record Official record
Conditions
Influenza, Human Prevention, Respiratory Syncytial Viruses Prevention
Interventions
Ad26.RSV.preF-based vaccine, Quadrivalent High-dose Influenza Vaccine, Placebo
Biological
Lead sponsor
Janssen Vaccines & Prevention B.V.
Industry
Eligibility
65 Years and older
Enrollment
777 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
19
States / cities
Long Beach, California • Hollywood, Florida • Port Orange, Florida + 14 more
Source: ClinicalTrials.gov public record
Updated May 25, 2025 · Synced Oct 25, 2026, 7:53 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Misoprostol Prior to Intrauterine Device (IUD) Insertion in Nulliparous Women

NCT01147497
View directory record Official record
Conditions
Contraception
Interventions
Misoprostol, Placebo
Drug
Lead sponsor
Emory University
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
78 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2011
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Jan 12, 2018 · Synced Oct 25, 2026, 7:53 AM EDT
Recruiting Phase 1 Interventional

Fecal Microbiota Transplant and Dietary Fiber Supplementation for the Treatment of Gut Graft Versus Host Disease

NCT05067595
View directory record Official record
Conditions
Intestinal Graft Versus Host Disease
Interventions
Colonoscopy, Fecal Microbiota Transplantation, Nutritional Supplementation, Survey Administration, Biospecimen Collection
Procedure · Biological · Dietary Supplement + 1 more
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Sep 11, 2026 · Synced Oct 25, 2026, 7:53 AM EDT
Withdrawn No phase listed Observational

RELISTOR's Effects on Opioid-Induced Constipation

NCT04930237
View directory record Official record
Conditions
OIC
Interventions
Relistor Injectable Product, Docusate Calcium, Bisacodyl, Milk of magnesia, Magnesium citrate, Senna, Enema
Drug
Lead sponsor
Methodist Health System
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Mar 23, 2026 · Synced Oct 25, 2026, 7:53 AM EDT
Active, not recruiting Phase 1Phase 2 Interventional Results available

A Phase I/II Study to Evaluate the Safety of Cellular Immunotherapy Using Autologous T Cells Engineered to Express a CD20-Specific Chimeric Antigen Receptor for Patients With Relapsed or Refractory B Cell Non-Hodgkin Lymphomas

NCT03277729
View directory record Official record
Conditions
Recurrent B-Cell Non-Hodgkin Lymphoma, Recurrent Chronic Lymphocytic Leukemia, Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Follicular Lymphoma, Recurrent Lymphoplasmacytic Lymphoma, Recurrent Mantle Cell Lymphoma, Recurrent Marginal Zone Lymphoma, Refractory B-Cell Non-Hodgkin Lymphoma, Refractory Diffuse Large B-Cell Lymphoma, Refractory Follicular Lymphoma, Refractory Lymphoplasmacytic Lymphoma, Refractory Mantle Cell Lymphoma, Refractory Transformed Non-Hodgkin Lymphoma, Recurrent Transformed B-Cell Non-Hodgkin Lymphoma, Recurrent Transformed Chronic Lymphocytic Leukemia, Refractory Marginal Zone Lymphoma, Refractory Transformed B-Cell Non-Hodgkin Lymphoma, Refractory Transformed Chronic Lymphocytic Leukemia, Recurrent Small Lymphocytic Lymphoma, Refractory Chronic Lymphocytic Leukemia, Refractory Small Lymphocytic Lymphoma, Recurrent Central Nervous System Lymphoma, Refractory Central Nervous System Lymphoma
Interventions
Chimeric Antigen Receptor T-Cell Therapy, Cyclophosphamide, Laboratory Biomarker Analysis, Leukapheresis, Fludarabine Phosphate
Biological · Drug · Other + 1 more
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2039
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jun 22, 2026 · Synced Oct 25, 2026, 7:53 AM EDT
Completed Not applicable Interventional

Palliative Oxygen for the Relief of Breathlessness

NCT00327873
View directory record Official record
Conditions
Dyspnea
Interventions
Oxygen, Medical Air
Other
Lead sponsor
National Health and Medical Research Council, Australia
Other
Eligibility
18 Years and older
Enrollment
240 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Dec 14, 2009 · Synced Oct 25, 2026, 7:53 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Micronutrients to Prevent Noise-induced Hearing Loss

NCT00808470
View directory record Official record
Conditions
Noise-Induced Hearing Loss
Interventions
beta-carotene, vitamins C and E, magnesium, Placebo
Drug · Other
Lead sponsor
University of Michigan
Other
Eligibility
18 Years to 35 Years
Enrollment
72 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2013
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated May 19, 2017 · Synced Oct 25, 2026, 7:53 AM EDT
Recruiting Phase 2 Interventional

Placebo-Controlled Trial of Urolithin A Supplementation in Men With Prostate Cancer Undergoing Radical Prostatectomy, URO-PRO Trial

NCT06022822
View directory record Official record
Conditions
Prostate Adenocarcinoma
Interventions
Biopsy Procedure, Biospecimen Collection, Placebo Administration, Urolithin A Supplement
Procedure · Drug · Dietary Supplement
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older · Male only
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
5
States / cities
Los Angeles, California • Chicago, Illinois • Durham, North Carolina + 1 more
Source: ClinicalTrials.gov public record
Updated Aug 25, 2026 · Synced Oct 25, 2026, 7:53 AM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Speech Motor Learning and Retention (Aim 1)

NCT06467305
View directory record Official record
Conditions
Speech
Interventions
continuous theta-burst stimulation (cTBS), Adaptation
Device · Behavioral
Lead sponsor
Yale University
Other
Eligibility
18 Years to 40 Years
Enrollment
160 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2029
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Feb 19, 2026 · Synced Oct 25, 2026, 7:53 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

H7N9 Mix and Match With MF59 in Healthy Elderly Persons

NCT02213354
View directory record Official record
Conditions
Avian Influenza
Interventions
MF59, Influenza Virus Vaccine, Monovalent A/H7N9 A/Shanghai/2/2013
Drug · Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
65 Years to 99 Years
Enrollment
479 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2016
U.S. locations
10
States / cities
Decatur, Georgia • Iowa City, Iowa • Baltimore, Maryland + 7 more
Source: ClinicalTrials.gov public record
Updated Jul 6, 2017 · Synced Oct 25, 2026, 7:53 AM EDT
Recruiting Phase 2 Interventional

HPV Vaccine, Imiquimod, and Metformin Combination Trial

NCT06686043
View directory record Official record
Conditions
Cervical Carcinoma, Vaginal Carcinoma, Vulvar Carcinoma, HPV (Human Papillomavirus)-Associated Carcinoma
Interventions
HPV vaccine, Imiquimod, and metformin combination therapy
Drug
Lead sponsor
Baylor College of Medicine
Other
Eligibility
18 Years to 64 Years · Female only
Enrollment
85 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
2
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Nov 13, 2024 · Synced Oct 25, 2026, 7:53 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Safety, Tolerability, and Immunogenicity of V110 or V114 Co-administered With a Booster Dose of mRNA-1273 in Healthy Adults (V110-911)

NCT05158140
View directory record Official record
Conditions
Pneumococcal Infection
Interventions
V110, V114, mRNA-1273, Placebo for V110, Placebo for V114
Biological
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
50 Years and older
Enrollment
850 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
42
States / cities
North Hollywood, California • Northridge, California • Paramount, California + 38 more
Source: ClinicalTrials.gov public record
Updated Jul 18, 2025 · Synced Oct 25, 2026, 7:53 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Optimizing the Temperature for Embryo Culture in In Vitro Fertilization

NCT01506089
View directory record Official record
Conditions
Infertility
Interventions
36 degrees Celsius
Other
Lead sponsor
Reproductive Medicine Associates of New Jersey
Other
Eligibility
18 Years to 41 Years · Female only
Enrollment
55 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2014
U.S. locations
2
States / cities
Morristown, New Jersey • Allentown, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 26, 2015 · Synced Oct 25, 2026, 7:53 AM EDT
Recruiting Phase 2 Interventional Accepts healthy volunteers

CMV-MVA Triplex Vaccination in HLA-Matched Related Stem Cell Donors for the Prevention of CMV Infection in Patients Undergoing Hematopoietic Stem Cell Transplant

NCT06059391
View directory record Official record
Conditions
Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Chronic Lymphocytic Leukemia, Chronic Myeloid Leukemia, BCR-ABL1 Positive, Hematopoietic and Lymphoid System Neoplasm, Hodgkin Lymphoma, Myelodysplastic Syndrome, Myelofibrosis, Myeloproliferative Neoplasm, Non-Hodgkin Lymphoma
Interventions
Allogeneic Hematopoietic Stem Cell Transplantation, Biospecimen Collection, Granulocyte Colony-Stimulating Factor, Hematopoietic Cell Transplantation Conditioning Regimen, Multi-peptide CMV-Modified Vaccinia Ankara Vaccine, Pheresis, Placebo Administration, Stem Cell Mobilization Therapy
Procedure · Drug · Biological
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years to 75 Years
Enrollment
216 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2028
U.S. locations
3
States / cities
Duarte, California • Atlanta, Georgia • Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 23, 2026 · Synced Oct 25, 2026, 7:53 AM EDT
Completed Not applicable Interventional Results available

Randomized DB Controlled Trial of Botulinum Toxin A in Hemiplegic Shoulder Pain and Spasticity

NCT00661089
View directory record Official record
Conditions
Post-stroke Shoulder Pain and Spasticity
Interventions
Botulinum Toxin Type A - OnabotulinumtoxinA, Placebo (Saline)
Drug
Lead sponsor
Shirley Ryan AbilityLab
Other
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2010
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Nov 13, 2020 · Synced Oct 25, 2026, 7:53 AM EDT
Withdrawn Phase 1 Interventional

Preventing de Novo Portal Vein Thrombosis With Antithrombin-III in Patients With Cirrhosis

NCT04055389
View directory record Official record
Conditions
Portal Vein Thrombosis, Cirrhosis, Liver
Interventions
Antithrombin III, Placebo
Drug · Other
Lead sponsor
Jonathan Stine
Other
Eligibility
18 Years to 75 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Hershey, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 10, 2022 · Synced Oct 25, 2026, 7:53 AM EDT
Recruiting Phase 2 Interventional

Fisetin to Improve Physical Function in Stage I-III Breast Cancer Survivors

NCT05595499
View directory record Official record
Conditions
Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8
Interventions
Biospecimen Collection, Fisetin, Placebo Administration, Quality-of-Life Assessment, Questionnaire Administration
Procedure · Drug · Other
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Eligibility
Female only
Enrollment
88 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
7
States / cities
Alhambra, California • Beverly Hills, California • Burbank, California + 4 more
Source: ClinicalTrials.gov public record
Updated Jul 17, 2026 · Synced Oct 25, 2026, 7:53 AM EDT